For instance, the pharmacological blockade of NLRP3 signaling has been found to exert beneficial effects in animal models of PD, MS, obesity, type 2 diabetes, arthritis, and colitis [10]. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.